AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	13.34	14.07	14.76	12.75	4.67
Research & Development	24.77	40.49	54.87	29.51	16.91
Other Operating Expenses	-	2.23	-	-	-
Total Operating Expenses	38.11	56.79	69.64	42.26	21.57
Operating Income	-38.11	-56.79	-69.64	-42.26	-21.57
Interest Income	2.93	5.47	4.86	-	0.07
Other Non-Operating Income (Expense)	0	0	0.04	1.31	-0.04
Total Non-Operating Income (Expense)	2.94	5.47	4.9	1.31	0.03
Pretax Income	-35.17	-51.32	-64.73	-40.96	-21.54
Net Income	-35.17	-51.32	-64.73	-42.78	-28.06
Net Income Attributable to Preferred Dividends	-	-	-	1.82	6.52
Net Income to Common	-35.17	-51.32	-64.73	-42.78	-28.06
Shares Outstanding (Basic)	30	30	24	15	3
Shares Outstanding (Diluted)	30	30	24	15	3
Shares Change (YoY)	1.30%	26.39%	53.85%	481.46%	2.71%
EPS (Basic)	-1.16	-1.72	-2.74	-2.79	-10.64
EPS (Diluted)	-1.16	-1.72	-2.74	-2.79	-10.64
Shares Outstanding	27.41	29.92	29.74	19.4	-
Free Cash Flow	-29.83	-49.26	-53.29	-33.46	-20.48
Free Cash Flow Per Share	-0.99	-1.65	-2.26	-2.18	-7.76
EBITDA	-38.11	-56.79	-69.64	-42.26	-21.57
EBIT	-38.11	-56.79	-69.64	-42.26	-21.57

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q